Related Experiment Video
Updated: Jul 9, 2026
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
A pre-emptive risk model for acute rejection in liver transplantation: an immunopharmacologic biomarker panel
Qin-Xin Li1, Jun-Xi Zhang1, Han Li2
1Department of Hepatobiliary and Pancreaticosplenic Surgery, Medical Research Center, Beijing Organ Transplant Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Introduction:
Acute cellular rejection (ACR) is a T cell-driven event in liver transplantation. Current monitoring relies on detecting graft injury, lacking tools for pre-emptive risk assessment based on the patient's real-time immune status.
Methods:
We developed an immunopharmacologic risk model in a retrospective cohort of 98 liver transplant recipients (18 with biopsy-proven ACR). The model integrated peripheral CD4+ T-cell percentage (flow cytometry) and tacrolimus trough level. Firth-penalized logistic regression was used for model development, with internal validation via bootstrapping.
Results:
The parsimonious model, comprising only CD4+ T-cell percentage and tacrolimus level, demonstrated good discrimination (AUC 0.774, 95% CI 0.674-0.874) and calibration. Critically, lead-time analysis revealed the model provided a median warning window of 8 days (IQR: 3.5 days) prior to biochemical injury onset. It offered significant incremental value over monitoring tacrolimus alone (AUC 0.774 vs. 0.694, ΔAUC=0.080, p=0.007) or CD4+ T cells alone (AUC 0.774 vs. 0.733, ΔAUC=0.041, p=0.014).
Conclusion:
We identify and validate a novel, clinically actionable immunopharmacologic biomarker panel for ACR. This model enables pre-emptive risk stratification by capturing the high-risk confluence of immune activation and subtherapeutic immunosuppression, paving the way for personalized immunotherapy in transplant recipients.
